Research Topics
| Per Soelberg SorensenSummaryAffiliation: Copenhagen University Hospital Country: Denmark Publications
| Collaborators
|
Detail Information
Publications
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trialPer Soelberg Sorensen
Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Lancet Neurol 8:519-29. 2009..Our aim was to assess the efficacy of oral methylprednisolone as an add-on therapy to subcutaneous interferon beta-1a to reduce the yearly relapse rate in patients with relapsing-remitting multiple sclerosis...- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabPer Soelberg Sørensen
Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet and Copenhagen University, Denmark
Mult Scler 18:143-52. 2012..Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development... 
The relationship between MRI and PET changes and cognitive disturbances in MSPer Soelberg Sørensen
Department of Neurology 2082, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
J Neurol Sci 245:99-102. 2006..Measurements of global NAA using multi-slice EPSI is a new promising method for measurement of the global neuron capacity and can be repeated with only little discomfort and without any risk for the patient...- Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MSP Soelberg Sorensen
Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Neurology 67:1681-3. 2006..High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032)... - The gap between effect of drugs and effectiveness of treatmentsPer Soelberg Sorensen
Copenhagen Multiple Sclerosis Research Center, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
J Neurol Sci 259:128-32. 2007..However, this may not be obtained from a single drug but may require combinations of drugs with different actions on the disease processes... - Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?P S Sorensen
Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Mult Scler 13:616-21. 2007..With affinity maturation, NAbs effectively prevent IFN-beta binding to its receptors also in vivo and, hence, abolish the treatment effect... - Intravenous polyclonal human immunoglobulins in multiple sclerosisPer Soelberg Sorensen
Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Neurodegener Dis 5:8-15. 2008.... - [Biological treatment of multiple sclerosis]Per Soelberg Sørensen
Rigshospitalet, Dansk Multipel Sclerose Center, Neurologisk Afdeling 2082, København Ø
Ugeskr Laeger 170:2156-9. 2008..However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate... - Oral fumarate for relapsing-remitting multiple sclerosisPer Soelberg Sorensen
Danish Multiple Sclerosis Research Center, Department of Neurology, Rigshospitalet, DK-2100, Copenhagen, Denmark
Lancet 372:1447-8. 2008 
Neutralizing antibodies against interferon-BetaPer Soelberg Sorensen
Danish Multiple Sclerosis Research Center Department of Neurology 2082, Copenhagen University Hospital Rigshospitalet, DK 2100 Copenhagen, Denmark
Ther Adv Neurol Disord 1:62-78. 2008..As low and medium titers are ambiguous treatment decisions in patients with low NAb titres should be guided by determination of in vivo mRNA MxA induction and clinical disease activity...- Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trialPer Soelberg Sorensen
Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Lancet Neurol 10:691-701. 2011..Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy... - Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosisP S Sørensen
Danish Multiple Sclerosis Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Eur J Neurol 12:817-27. 2005..In patient with NABs, measurements should be repeated, and therapy with IFN-beta should be discontinued in patients with high titres of NABs sustained at repeated measurements with 3- to 6-month intervals (Level A recommendation)... - Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysisP S Sorensen
MS Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Eur J Neurol 9:557-63. 2002..IVIG could be considered in patients who do not tolerate or are unwilling to take the approved injectable medications, but additional studies are needed to establish the role of IVIG in the management of multiple sclerosis... - Early-stage multiple sclerosis : what are the treatment options?Per Soelberg Sorensen
Copenhagen MS Centre, The Neuroscience Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Drugs 64:2021-9. 2004..However, further prolonged studies are needed to investigate the long-term benefit of early-stage treatment in MS... - Antibodies to IFN-beta: the Danish National IFN-beta ProjectPer Soelberg Sorensen
Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Neurology 61:S27-8. 2003 - IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MSP Soelberg Sorensen
MS Research Unit, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
Neurology 63:2028-33. 2004..To investigate if IV immunoglobulins (IVIg) in combination with methylprednisolone make recovery from a relapse faster and more complete than methylprednisolone alone. Design/.. - Multiple sclerosis: pathophysiology revisitedPer Soelberg Sorensen
Copenhagen Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Lancet Neurol 4:9-10. 2005 - Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisPer Soelberg Sorensen
Department of Neurology, Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark
Lancet 362:1184-91. 2003..We aimed to assess the clinical effect of neutralising antibodies... - Appearance and disappearance of neutralizing antibodies during interferon-beta therapyP Soelberg Sorensen
Copenhagen MS Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
Neurology 65:33-9. 2005.... - [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis]Soelberg Sørensen
Sclerose Forskningsenheden, Københavns MS Center, Neurologisk Afdeling 2082, H S Rigshospitalet
Ugeskr Laeger 166:3606-9. 2004 - IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesionsSigne Humle Jorgensen
Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet sect 6311, 2100 Copenhagen, Denmar
Exp Brain Res 178:462-9. 2007..In conclusion, the results indicate that significant extravasation of IVIG to the CNS only occurs when blood-brain barrier function is compromised during EAE... - Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosisBodil Petersen
Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Mult Scler 12:247-52. 2006..CONCLUSION: NABs against IFNbeta, especially with high titres, tend to persist for a long time after discontinuation of IFNbeta therapy. NABs should always be measured before reinstitution of IFNbeta treatment in NAB-positive patients... - Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosisHenrik Kahr Mathiesen
Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
Magn Reson Med 53:750-9. 2005..The reproducibility of the technique makes it a promising tool for future longitudinal spectroscopic studies of MS... - The role of intravenous immunoglobulin in the treatment of multiple sclerosisPer Soelberg Sorensen
MS Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark
J Neurol Sci 206:123-30. 2003.... - Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylacticallySigne Humle Jorgensen
Danish MS Centre, Copenhagen University Hospital, Rigshospitalet sect 9202, DK 2100 Copenhagen, Denmark
Neurol Res 27:591-7. 2005..EAE was induced in susceptible Dark Agouti rats by active immunization with a spinal cord homogenate, and infusions of 1 g/kg IVIG were given prophylactically or therapeutically... - Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?Nils Koch-Henriksen
Department of Neurology, Aarhus University Hospital in Aalborg, Denmark
J Neurol Sci 311:58-63. 2011..In addition, we observed in most regions a profound increase in female incidence of MS. The last observation should prompt epidemiological studies focusing on change in female life style... - Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitisSigne Humle Jorgensen
Copenhagen MS Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
J Neurol Sci 233:61-5. 2005..IVIG is, therefore, presently regarded as a second-line therapy of MS... - Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyPer Soelberg Sorensen
Neurology 69:1552; author reply 1553. 2007 - Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell
J Int Med Res 36:204-8; author reply 208-10. 2008 - Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosisTimothy K Vartanian
Multiple Sclerosis Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
Neurology 63:S42-9. 2004..Long-term prospective studies are needed to further define the clinical effects of NAbs on patients receiving disease-modifying therapies for MS... - Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosisHenrik Kahr Mathiesen
Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
Arch Neurol 63:533-6. 2006..Whole-brain N-acetyl aspartate (NAA), a measure of neuronal function, can be assessed by multislice echo-planar spectroscopic imaging... - Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Arch Neurol 62:1519-30. 2005.... - Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans P Hartung
Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
J Neurol 254:827-37. 2007.... - Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patientsHanne F Harbo
Institute of Immunology, Rikshospitalet University Hospital, 0027 Oslo, Norway
J Neuroimmunol 143:101-6. 2003..Usable data were achieved from the same 3331 markers in both screens. Nine markers from eight genomic regions (1p33, 3q13, 6p21, 6q14, 7p22, 9p21, 9q21 and Xq22) were identified as potentially associated with MS in both screens... - Remyelination is extensive in a subset of multiple sclerosis patientsPeter Patrikios
Center for Brain Research, Medical University of Vienna, Vienna, Austria
Brain 129:3165-72. 2006..These results suggest that the variable and patient-dependent extent of remyelination must be considered in the design of future clinical trials aimed at promoting CNS repair...